Will Zepatier by Merck Monopolize Hepatitis C Market?

Will Zepatier by Merck Monopolize Hepatitis C Market? In October 2014, Gilead launched Harvoni to cover more market in a single-tablet formulation. With Harvoni's launch, the need for the interferon has been completely eliminated. The miracle drug reduced the treatment … Continue reading

Merck to Present New Data on Investigational Chronic Hepatitis C Treatment

Merck to Present New Data on Investigational Chronic Hepatitis C Treatment … KENILWORTH, N.J., Oct 20, 2015 (BUSINESS WIRE) — Merck MRK, +1.67% known as MSD outside the United States and Canada, today announced that new data from clinical trials … Continue reading

Study: Merck hep C combo effective in kidney disease patients

Study: Merck hep C combo effective in kidney disease patients Earlier this year, the FDA granted Merck breakthrough status for its combined grazoprevir/elbasvir combination medication for treatment of hepattis C (HCV). Merck is also targeting patients with severe kidney impairment … Continue reading

Merck Gets Breakthrough Designation for Hepatitis C Drugs

Merck Gets Breakthrough Designation for Hepatitis C Drugs In 2013, the FDA had granted grazoprevir and elbasvir breakthrough status for their use on patients with hepatitis C genotype 1. The new breakthrough designations are for patients infected with chronic HCV … Continue reading